Literature DB >> 25546793

Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis.

J Gamez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546793      PMCID： PMC4285522          DOI： 10.1111/cei.12542

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  11 in total

1.  Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis.

Authors:  A I Qureshi; M A Choudhry; M S Akbar; Y Mohammad; H C Chua; A M Yahia; J A Ulatowski; D A Krendel; R T Leshner
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

2.  Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis.

Authors:  C-S Huang; H-S Hsu; K-P Kao; M-H Huang; B-S Huang
Journal:  Acta Neurol Scand       Date:  2003-08       Impact factor: 3.209

3.  A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis.

Authors:  Paul Jensen; Vera Bril
Journal:  J Clin Neuromuscul Dis       Date:  2008-03

4.  Surgical outcome in thymic tumors with myasthenia gravis after plasmapheresis--a comparative study.

Authors:  Binay Krishna Sarkar; Pratim Sengupta; Uday Narayan Sarkar
Journal:  Interact Cardiovasc Thorac Surg       Date:  2008-08-05

5.  Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.

Authors:  P Gajdos; S Chevret; B Clair; C Tranchant; C Chastang
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

6.  Guidelines for the treatment of autoimmune neuromuscular transmission disorders.

Authors:  G O Skeie; S Apostolski; A Evoli; N E Gilhus; I K Hart; L Harms; D Hilton-Jones; A Melms; J Verschuuren; H W Horge
Journal:  Eur J Neurol       Date:  2006-07       Impact factor: 6.089

7.  Myasthenic crisis: clinical features, complications and mortality.

Authors:  J M K Murthy; A K Meena; G V S Chowdary; Jaishree T Naryanan
Journal:  Neurol India       Date:  2005-03       Impact factor: 2.117

Review 8.  Myasthenia gravis: past, present, and future.

Authors:  Bianca M Conti-Fine; Monica Milani; Henry J Kaminski
Journal:  J Clin Invest       Date:  2006-11       Impact factor: 14.808

Review 9.  Myasthenic crisis.

Authors:  A Chaudhuri; P O Behan
Journal:  QJM       Date:  2008-12-05

10.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570
View more
  1 in total

1.  Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis.

Authors:  Josep Gamez; María Salvadó; Francesc Carmona; Miriam de Nadal; Laura Romero; Daniel Ruiz; Alberto Jáuregui; Olga Martínez; Javier Pérez; Pilar Suñé; María Deu
Journal:  Ther Adv Neurol Disord       Date:  2019-07-17       Impact factor: 6.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.